Literature DB >> 27842696

Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Dan Călugăru1, Mihai Călugăru1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27842696     DOI： 10.1016/j.ajo.2016.07.029

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  6 in total

1.  High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-08       Impact factor: 3.117

2.  Comment on "Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration".

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

3.  Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

4.  Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-21       Impact factor: 3.117

5.  Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-06       Impact factor: 3.117

6.  The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-07       Impact factor: 3.117
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.